Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Chief Messaging Officer” Pitts Will Centralize Agency Communications

Executive Summary

FDA Associate Commissioner for External Relations Peter Pitts will coordinate FDA's communications within the commissioner's office and across the agency's centers

You may also be interested in...



FDA External Relations Head Pitts Will Leave Agency For New York PR Firm

FDA Associate Commissioner for External Relations Peter Pitts is leaving after 14 months at the agency to join the public relations firm Manning, Selvage & Lee

FDA External Relations Head Pitts Will Leave Agency For New York PR Firm

FDA Associate Commissioner for External Relations Peter Pitts is leaving after 14 months at the agency to join the public relations firm Manning, Selvage & Lee

FDA Invites Manufacturers, Ad Agencies To Discuss DTC Ad Designs

FDA would like to consult with pharmaceutical companies and their advertising agencies early on in the development of direct-to-consumer advertising campaigns

Related Content

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel